Literature DB >> 35186374

Impact of Regions with COVID-19 Cases on COVID-Zero Regions by Population Mobility - Worldwide, 2021.

Lianhao Wang1, Shiyi Wang2, Xiangyu Zhang1, Zhongwei Jia1,3,4.   

Abstract

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC?: Reducing population mobility and increasing the vaccination rate for severe acute respiratory syndrome coronavirus 2 can decrease the transmission of coronavirus disease 2019 (COVID-19). WHAT IS ADDED BY THIS REPORT?: In order to reduce the incidence of COVID-19 to the levels of influenza after restoring normal mobility, the efficacy against infection needs to be increased to 40% and the efficacy against symptomatic disease needs to be increased to 90%. The efficacy against infection has a more important impact compared to efficacy against symptomatic disease or death on the transmission of COVID-19 at the population level. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE?: The population should continue maintaining non-pharmaceutical interventions and minimize international movement to prevent transmission of COVID-19. Furthermore, developing new vaccines or promoting booster vaccinations should be considered to increase efficacy. Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022.

Entities:  

Keywords:  COVID-19; Epidemic dynamics model; Population mobility; Vaccine

Year:  2022        PMID: 35186374      PMCID: PMC8837462          DOI: 10.46234/ccdcw2022.012

Source DB:  PubMed          Journal:  China CDC Wkly        ISSN: 2096-7071


  2 in total

1.  Exponential growth, high prevalence of SARS-CoV-2, and vaccine effectiveness associated with the Delta variant.

Authors:  David Haw; Haowei Wang; Oliver Eales; Paul Elliott; Caroline E Walters; Kylie E C Ainslie; Christina Atchison; Claudio Fronterre; Peter J Diggle; Andrew J Page; Alexander J Trotter; Sophie J Prosolek; Deborah Ashby; Christl A Donnelly; Wendy Barclay; Graham Taylor; Graham Cooke; Helen Ward; Ara Darzi; Steven Riley
Journal:  Science       Date:  2021-12-17       Impact factor: 47.728

2.  Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile.

Authors:  Alejandro Jara; Eduardo A Undurraga; Cecilia González; Fabio Paredes; Tomás Fontecilla; Gonzalo Jara; Alejandra Pizarro; Johanna Acevedo; Katherine Leo; Francisco Leon; Carlos Sans; Paulina Leighton; Pamela Suárez; Heriberto García-Escorza; Rafael Araos
Journal:  N Engl J Med       Date:  2021-07-07       Impact factor: 91.245

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.